XYXiaoyang Yue

Xiaoyang Yue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaoyang Yue has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Frank Petersen

    Priority Area Asthma & Allergy, Research Center Borstel, 23845 Borstel, Germany; Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Germany

    5 shared publications
  • Xinhua Yu

    Department of Genetics and Prenatal Diagnosis, Hainan Women and Children’s Medical Center, Haikou, Hainan, China

    4 shared publications
  • Fengyuan Deng

    Key Laboratory of Basic Research on Regional Diseases, College of Basic Medical Science Guangxi Medical University Guangxi China

    3 shared publications
  • Gabriela Riemekasten

    Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang, China

    3 shared publications
  • Junfeng Zheng

    Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang, China

    3 shared publications
  • Junping Yin

    Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), Borstel, Germany

    3 shared publications

Latest Publications

  • Structural Optimizations on the Scaffold of 7 H ‐Pyrrolo[2,3‐ d ]Pyrimidine to Develop Potent iNOS Inhibitors With Improved Antiarthritis Activity In Vivo

    by Wenchu Wang, Tingsheng Qin, Xianjing Feng, Mengyang Xu, Zhen Ling, Xin Xie, Min Zhang, Yanqin Huang, Jiayuan Luo, Sisi Cao, et al.

    Inducible nitric oxide synthase (iNOS) is an attractive target to develop drugs for the treatment of rheumatoid arthritis (RA), whose overexpression leads to the release of abundant NO. In this study, a series of compounds were designed and synthesized bearing the scaffold of 7 H ‐pyrrolo[2,3‐ d ]pyrimidine to improve CLogP values and in vivo anti‐inflammatory activity via molecular hybridization, whose derivatives in a previous study demonstrated good inhibition toward NO production but high CLogP values and weak potency in vivo. Among them, N3b effectively suppressed NO production in a concentration‐dependent manner (IC 50 = 4.66 ± 0.19 μM) in LPS‐induced RAW264.7 cells. Mechanically, N3b mildly inhibited the protein expression of iNOS (IC 50 = 13.60 ± 0.39 μM), without remarkable influence on the mRNA levels of iNOS or other classical pro‐inflammatory cytokines including IL‐1β, IL‐6, and TNF‐α at the high concentration of 30 µM. With favorable drug‐likeness, N3b significantly alleviated paw edema at the dose of 30 mg/kg in the acute inflammation model and mitigated paw swelling and joint damage at a dosage of 10 mg/kg in the chronic arthritis model. Furthermore, N3b did not cause any obvious weight loss and pathological changes of important organs in treated mice, indicating that N3b is a potent candidate iNOS inhibitor for the treatment of RA.


  • Open Access

    Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching

    by Xiaoyang Yue, Junping Yin, Xiaoqing Wang, Harald Heidecke, Alexander Maximilian Hackel, Xiaoru Dong, Brigitte Kasper, Lifang Wen, Liang Zhang, Kai Schulze-Forster, et al.

    Objective To determine contributions and functions of autoantibodies (Abs) directed to the angiotensin receptor type 1 (AT1R), which are suggested to be involved in the pathogenesis of AT1R Abs-related diseases such as systemic sclerosis (SSc). Methods C57BL/6J mice were immunised with membrane-embedded human AT1R or empty membrane as control. Mice deficient for CD4+ or CD8+ T cells and B cells were immunised with membrane-embedded AT1R or an AT1R peptide proposed to be a dominant T cell epitope. A monoclonal (m)AT1R Ab was generated by hybridoma technique and transferred into C57BL/6J and AT1Ra/b knockout mice. The induced phenotype was examined by histology, immunohistochemistry, immunofluorescence, apoptosis assay and ELISA. In vitro, Abs responses towards AT1R were measured in cells of different origins and species. Results AT1R-immunised mice developed perivascular skin and lung inflammation, lymphocytic alveolitis, weak lung endothelial apoptosis and skin fibrosis accompanied by Smad2/3 signalling, not present in controls or mice deficient for CD4+ T and B cells. The AT1R peptide 149–172 provoked lung inflammation. Application of the mAT1R Ab induced skin and lung inflammation, not observed in AT1Ra/b knockout mice. In vitro, AT1R Abs activated rat cardiomyocytes and human monocytes, enhanced angiotensin II-mediated AT1R activation in AT1R-transfected HEK293 cells via AT1R binding and mAT1R Ab-activated monocytes mediated the induction of profibrotic markers in dermal fibroblasts. Conclusion Our immunisation strategy successfully induced AT1R Abs, contributing to inflammation and, possibly, to fibrosis via activation of AT1R. Therefore, AT1R Abs are valuable targets for future therapies of SSc and other AT1R Ab-related diseases.


  • Recent advances in mouse models for systemic sclerosis

    by Xiaoyang Yue, Xinhua Yu, Frank Petersen, Gabriela Riemekasten


  • Open Access

    Gene Expression Profiling of Lacrimal Glands Identifies the Ectopic Expression of MHC II on Glandular Cells as a Presymptomatic Feature in a Mouse Model of Primary Sjögren's Syndrome

    by Junping Yin, Junfeng Zheng, Fengyuan Deng, Wenjie Zhao, Yan Chen, Qiaoniang Huang, Renliang Huang, Lifang Wen, Xiaoyang Yue, Frank Petersen, et al.

    Ectopic expression of MHC II molecules on glandular cells is a feature of primary Sjögren's syndrome (pSS). However, the cause of this ectopic expression and its potential role in the pathogenesis of the disease remains elusive. Here, we report that ectopic expression of MHC II molecules on glandular cells represents an early presymptomatic event in a mouse model of pSS induced by immunization of Ro60_316-335 peptide emulsified in TiterMax® as an adjuvant. Ectopic expression of MHC II was induced by TiterMax® but not by complete freund's adjuvant (CFA). Furthermore, immunization with Ro60_316-335 peptide emulsified in TiterMax®, but not in CFA, induced a pSS-like disease in mice. Our results suggests that ectopic expression of MHC II molecules on glandular cells represents a presymptomatic feature of pSS and that such ectopic expression can be induced by exogenous factors. In addition, this study also provides a novel mechanism how adjuvants can amplify immune responses.


  • Open Access

    B Cells Are Indispensable for a Novel Mouse Model of Primary Sjögren’s Syndrome

    by Junfeng Zheng, Qiaoniang Huang, Renliang Huang, Fengyuan Deng, Xiaoyang Yue, Junping Yin, Wenjie Zhao, Yan Chen, Lifang Wen, Jun Zhou, et al.

    Primary Sjögren’s syndrome (pSS) is characterized by a panel of autoantibodies, while it is not clear whether B cells and autoantibodies play an essential role in pathogenesis of the disease. Here, we report a novel mouse model for pSS which is induced by immunization with the Ro60_316-335 peptide containing a predominant T cell epitope. After immunization, mice developed several symptoms mimicking pSS, including a decreased secretion of tears, lymphocytic infiltration into the lacrimal glands, autoantibodies, and increased levels of inflammatory cytokines. Disease susceptibility to this novel mouse model varies among strains, where C3H/HeJ (H2-k) and C3H/HeN (H2-k) are susceptible while DBA/1 (H2-q) and C57BL/6 (H2-b) are resistant. Depletion of B cells using anti-CD20 monoclonal antibodies prevented C3H/HeN mice from development of the pSS-like disease. In addition, HLA-DRB1*0803, a pSS risk allele, was predicted to bind to the hRo60_308-328 which contains a predominant T cell epitope of human Ro60. Therefore, this study provides a novel mouse model for pSS and reveals an indispensable role of B cells in this model. Moreover, it suggests that T cell epitope within Ro60 antigen is potentially pathogenic for pSS.


  • Dysregulated homeostasis of target tissues or autoantigens - A novel principle in autoimmunity

    by Frank Petersen, Xiaoyang Yue, Gabriela Riemekasten, Xinhua Yu


  • The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms

    by Wenjie Zhao, Xiaoyang Yue, Kuai Liu, Junfeng Zheng, Runda Huang, Jun Zou, Gabriela Riemekasten, Frank Petersen, Xinhua Yu

    Pulmonary fibrosis (PF) is one of the leading causes of death in systemic sclerosis (SSc) patients. Although all SSc patients are characterized by autoimmunity, only part of them suffer from PF, suggesting that beside autoimmunity, some additional factors are involved in the initiation of PF in SSc. In this study, we aimed to identify genetic polymorphisms associated with the status of PF in SSc. We performed that an exhaustive search of the PubMed database was performed to identify eligible studies. Then, a comprehensive meta-analysis was performed by comparing PF+-SSc and PF−-SSc patients to identify genetic polymorphisms associated with the status of PF in SSc. Among eight SSc-associated susceptibility polymorphisms which were applied for meta-analysis, IRF5 rs2004640 polymorphism (OR 1.12; 95% CI 1.02–1.22, P = 1.39 × 10−2), STAT4 rs7574865 polymorphism (OR 1.25; 95% CI 1.07–1.47, P = 5.3 × 10−3), IRAK1 rs1059702 polymorphism (OR 1.20; 95% CI 1.05–1.37, P = 0.007), and CTGF G-945C polymorphism (OR 1.42; 95% CI 1.18–1.71, P = 0.002) are associated with PF status in SSc, while TNFAIP3 rs5029939, CD226 rs763361, CD247 rs2056626, and IRF5 rs10488631 polymorphisms are not. Since IRF5, STAT4, and IRAK1 are important regulatory factors in the control of innate immune responses and CTGF is involved in the synthesis of extracellular matrix, these results suggest a role of the innate immunity and matrix compounds in the pathogenesis of PF in SSc.


  • Cholesterol modulates function of connexin 43 gap junction channel via PKC pathway in H9c2 cells

    by Jun Zou, Xiao-Yang Yue, Sheng-Chao Zheng, Guangwei Zhang, He Chang, Yan-Chun Liao, Ye Zhang, Mao-Qiang Xue, Zhi Qi